An internal standard for the quantification of retatrutide
Related Products And Services
Unlabeled Version(s)
45527Retatrutide39747Retatrutide (sodium salt)
Technical Support & Resources

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Retatrutide-d7 (trifluoroacetate salt)

Item No. 46531

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
L-tyrosyl-2-methylalanyl-L-glutaminylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L-alpha-aspartyl-L-tyrosyl-L-seryl-L-isoleucyl-2-methyl-L-leucyl-(L-leucyl-4,5,5,5,5′,5′,5′-d7)-L-alpha-aspartyl-L-lysyl-N6-[N-(19-carboxy-1-oxononadecyl)-L-gamma-glutamyl-2-[2-(2-aminoethoxy)ethoxy]acetyl]-L-lysyl-L-alanyl-L-glutaminyl-2-methylalanyl-L-alanyl-L-phenylalanyl-L-isoleucyl-L-alpha-glutamyl-L-tyrosyl-L-leucyl-L-leucyl-L-alpha-glutamylglycylglycyl-L-prolyl-L-seryl-L-serylglycyl-L-alanyl-L-prolyl-L-prolyl-L-prolyl-L-serinamide, ditrifluoroacetate salt
Molecular Formula
C221H335D7N46O68 • 2CF3COOH
Formula Weight
4966.5
Purity
≥99% deuterated forms (d1-d7)
Formulation (Request formulation change)
A solid
SMILES
OC[C@@H](C(N)=O)NC([C@H]1N(C([C@H]2N(C([C@H]3N(C([C@H](C)NC(CNC([C@H](CO)NC([C@H](CO)NC([C@H]4N(C(CNC(CNC([C@H](CCC(O)=O)NC([C@H](CC(C)C)NC([C@H](CC(C)C)NC([C@H](CC5=CC=C(O)C=C5)NC([C@H](CCC(O)=O)NC([C@H]([C@@H](C)CC)NC([C@H](CC6=CC=CC=C6)NC([C@H](C)NC(C(C)(C)NC([C@H](CCC(N)=O)NC([C@H](C)NC([C@H](CCCCNC(COCCOCCNC(CC[C@@H](C(O)=O)NC(CCCCCCCCCCCCCCCCCCC(O)=O)=O)=O)=O)NC([C@H](CCCCN)NC([C@H](CC(O)=O)NC([C@H](CC(C([2H])([2H])[2H])([2H])C([2H])([2H])[2H])NC([C@@](CC(C)C)(C)NC([C@H]([C@@H](C)CC)NC([C@H](CO)NC([C@H](CC7=CC=C(O)C=C7)NC([C@H](CC(O)=O)NC([C@H](CO)NC([C@H]([C@H](O)C)NC([C@H](CC8=CC=CC=C8)NC([C@H]([C@H](O)C)NC(CNC([C@H](CCC(N)=O)NC(C(C)(C)NC([C@H](CC9=CC=C(O)C=C9)N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)CCC4)=O)=O)=O)=O)=O)CCC3)=O)CCC2)=O)CCC1)=O.OC(C(F)(F)F)=O.OC(C(F)(F)F)=O
InChi Code
InChI=1S/C221H342N46O68.2C2HF3O2/c1-23-124(11)179(208(322)241-144(83-88-176(291)292)192(306)245-150(105-134-69-75-137(276)76-70-134)196(310)244-148(100-121(5)6)194(308)243-147(99-120(3)4)193(307)240-142(82-87-175(289)290)187(301)230-110-169(282)229-113-173(286)264-92-51-61-161(264)206(320)253-158(116-270)203(317)251-157(115-269)189(303)232-111-170(283)233-128(15)212(326)266-94-53-63-163(266)214(328)267-95-54-64-164(267)213(327)265-93-52-62-162(265)207(321)250-156(114-268)183(226)297)258-200(314)152(103-131-55-41-39-42-56-131)242-185(299)127(14)235-216(331)219(18,19)262-205(319)145(80-85-166(225)279)237-184(298)126(13)234-190(304)140(60-48-50-90-227-172(285)119-335-98-97-334-96-91-228-167(280)86-81-146(215(329)330)236-168(281)65-45-37-35-33-31-29-27-25-26-28-30-32-34-36-38-46-66-174(287)288)238-191(305)141(59-47-49-89-222)239-198(312)154(107-177(293)294)247-195(309)149(101-122(7)8)256-218(333)221(22,109-123(9)10)263-211(325)180(125(12)24-2)259-204(318)160(118-272)252-197(311)151(106-135-71-77-138(277)78-72-135)246-199(313)155(108-178(295)296)248-202(316)159(117-271)254-210(324)182(130(17)274)260-201(315)153(104-132-57-43-40-44-58-132)249-209(323)181(129(16)273)257-171(284)112-231-188(302)143(79-84-165(224)278)255-217(332)220(20,21)261-186(300)139(223)102-133-67-73-136(275)74-68-133;2*3-2(4,5)1(6)7/h39-44,55-58,67-78,120-130,139-164,179-182,268-277H,23-38,45-54,59-66,79-119,222-223H2,1-22H3,(H2,224,278)(H2,225,279)(H2,226,297)(H,227,285)(H,228,280)(H,229,282)(H,230,301)(H,231,302)(H,232,303)(H,233,283)(H,234,304)(H,235,331)(H,236,281)(H,237,298)(H,238,305)(H,239,312)(H,240,307)(H,241,322)(H,242,299)(H,243,308)(H,244,310)(H,245,306)(H,246,313)(H,247,309)(H,248,316)(H,249,323)(H,250,321)(H,251,317)(H,252,311)(H,253,320)(H,254,324)(H,255,332)(H,256,333)(H,257,284)(H,258,314)(H,259,318)(H,260,315)(H,261,300)(H,262,319)(H,263,325)(H,287,288)(H,289,290)(H,291,292)(H,293,294)(H,295,296)(H,329,330);2*(H,6,7)/t124-,125-,126-,127-,128-,129+,130+,139-,140-,141-,142-,143-,144-,14
InChi Key
AWXLHYWQQYIBDC-XTMVTXAQSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    1 mg

    $1,599

    Add
    Cayman Chemical
    Explore Obesity & Metabolic Disease Resources

    Discover high-quality research tools to investigate GLP-1 mechanisms and next-generation metabolic targets.

    OBESITY RESEARCH SOLUTIONS
    Product Description

    Retatrutide-d7 is intended for use as an internal standard for the quantification of retatrutide (Item No. 45527 | 39747) by GC- or LC-MS. Retatrutide is a triple agonist of the glucagon receptor (GCGR), glucagon-like peptide 1 receptor (GLP-1R), and gastric inhibitory polypeptide receptor (GIP receptor), also known as the glucose-dependent insulinotropic polypeptide receptor.1 It induces cAMP accumulation in HEK293 cells expressing the human GCGR, GLP-1R, or GIP receptor (EC50s = 5.79, 0.775, and 0.0643 nM, respectively). Retatrutide (0.1-30 nmol/kg) decreases plasma glucose levels in an intraperitoneal glucose tolerance test in mice. It decreases body weight, calorie intake, fat mass, and lean mass in a mouse model of diet-induced obesity in a dose-dependent manner. Acute administration of retatrutide (10 nmol/kg) delays gastric emptying and chronic administration for 10 days decreases food intake and body weight in mice.2

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Coskun, T., Urva, S., Roell, W.C., et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept. Cell Metab. 34(9), 1234-1247 (2022).

    2. Urva, S., O'Farrell, L., Du, Y., et al. The novel GIP, GLP-1 and glucagon receptor agonist retatrutide delays gastric emptying. Diabetes Obes. Metab. 25(9), 2784-2788 (2023).